Novartis Reports Phase 2 Data for Avacopan in Ankylosing spondylitis

Novartis today announced Phase 2 results for avacopan in patients with ankylosing spondylitis. The study demonstrated that avacopan reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of ankylosing spondylitis and support the continued development of avacopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.